BLUEPRINT MEDICINES CORP's ticker is BPMC and the CUSIP is 09627Y109. A total of 221 filers reported holding BLUEPRINT MEDICINES CORP in Q2 2023. The put-call ratio across all filers is 2.57 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,163,497 | -20.6% | 23,168 | -0.1% | 0.15% | -27.2% |
| Q2 2023 | $1,465,861 | +40.5% | 23,194 | +0.0% | 0.20% | +43.3% |
| Q1 2023 | $1,043,093 | -18.2% | 23,185 | -20.4% | 0.14% | -31.9% |
| Q4 2022 | $1,275,660 | +7.8% | 29,118 | +62.2% | 0.21% | +15.6% |
| Q3 2022 | $1,183,000 | +378.9% | 17,948 | +363.3% | 0.18% | +752.4% |
| Q1 2022 | $247,000 | -94.5% | 3,874 | -91.6% | 0.02% | -93.5% |
| Q1 2021 | $4,473,000 | -27.4% | 46,000 | -16.2% | 0.32% | -22.8% |
| Q4 2020 | $6,159,000 | +3.0% | 54,918 | -14.9% | 0.42% | +5.3% |
| Q3 2020 | $5,979,000 | +11.1% | 64,500 | -6.6% | 0.40% | +7.9% |
| Q2 2020 | $5,384,000 | -3.7% | 69,031 | -27.8% | 0.37% | -17.4% |
| Q1 2020 | $5,592,000 | +14.4% | 95,627 | +56.8% | 0.44% | +47.2% |
| Q4 2019 | $4,887,000 | +15.3% | 61,000 | +5.7% | 0.30% | +19.4% |
| Q3 2019 | $4,239,000 | -22.1% | 57,700 | +0.1% | 0.25% | -21.5% |
| Q2 2019 | $5,439,000 | – | 57,660 | – | 0.32% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Boxer Capital, LLC | 705,159 | $12,728,000 | 12.46% |
| BVF INC/IL | 2,640,251 | $47,657,000 | 11.79% |
| Casdin Capital, LLC | 321,300 | $5,799,000 | 6.66% |
| Opaleye Management Inc. | 220,000 | $3,971,000 | 2.48% |
| PFM Health Sciences, LP | 1,420,511 | $25,640,000 | 0.79% |
| Perceptive Advisors | 404,404 | $7,299,000 | 0.64% |
| Partner Investment Management, L.P. | 18,788 | $339,000 | 0.55% |
| Visium Asset Management, LP | 1,265,025 | $22,834,000 | 0.39% |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 661,717 | $11,944,000 | 0.39% |
| Virtus ETF Advisers LLC | 10,484 | $189,000 | 0.26% |